Magrolimab Plus Azacitidine Results in Promising Activity in Higher-Risk MDS Patients

In a new article published today in the Journal of Clinical Oncology, Moffitt Cancer Center physician-scientists, in collaboration with institutions from across the United States and the United Kingdom, share promising phase 1b trial results of a new combination therapy — magrolimab + azacitidine — for patients with higher-risk MDS.

Investigational Combo Therapy Shows Benefit for TP53 Mutant MDS and Acute Myeloid Leukemia Patients

Moffitt Cancer Center is leading a national, multicenter clinical trial investigating a new therapy option for this group of patients. It builds upon the standard of care therapy, combining eprenetapopt (APR-246) with the chemotherapy azacitidine. Results of the phase 1b/2 trial to determine the safety, recommended dose and efficacy of the combination therapy were published in the Journal of Clinical Oncology.